Keywords
How to Cite
Abstract
Calcium channel antagonists have been reported to reduce blood pressure in those individuals at risk of cardiac and cerebrovascular events. There is no specific study available regarding the role of electrolyte alterations in blood pressure lowering effects of nifedipine. The present study was designed to investigate the role of electrolyte homeostasis, changes in ouabain-sensitive Na+ K+ adenosine triphosphatase (ATPase) activity, and net sodium efflux and potassium influx across blood cell membranes. Rats were divided into two experimental groups . Nifedipine (20mg/ kg body weight ) was administered by gastric tube to the test group . Control group received same volume of deionize water .The intra-erythrocyte sodium, serum sodium, potassium, calcium and sodium, calcium content of heart and kidney tissues were decreased significantly. Whereas, intra-erythrocyte potassium was slightly decreased or remained normal in nifedipine treated rats as compared to normal healthy rats. The Na - K - ATPase activity, serum magnesium, potassium and magnesium content in heart and kidney tissues were increased significantly. Results confirmed that nifedipine represses ion channels, transporters and calcium-binding proteins in tissues. Erythrocyte studies indicate that nifedipine blocks the entrance of calcium into the cells but also stimulate Na - K - ATPase activity, resulting in reduction of intracellular sodium concentration, thus suggesting direct nifedipine-induced blood pressure reduction.
References
Stone PH. The promise of nifedipine. J Cardiovasc Med 1982; 7: 181-96.
Hornung RS, Gould BA, Jones RI, Sonecha TN, Raftery EB. Nifedipine tablets for systemic hypertension-a study using continuous ambulatory intra-arterial recoding. Am J Cardiol 1983; 51: 1323-7. http://dx.doi.org/10.1016/0002-9149(83)90306-5
Scholze JE. Differential therapy with calcium antagonists. Herz 2003; 28: 754-63. http://dx.doi.org/10.1007/s00059-003-2504-x
Pontremoli R, Leoncini G, Parodi A. Use of nifedipine in the treatment of hypertension. Expert Rev Cardiovasc Ther 2005; 3: 43-50. http://dx.doi.org/10.1586/14779072.3.1.43
Reams GP. Do calcium channel blockers have renal protective effects?. Drugs Aging 1994; 5: 263–87. http://dx.doi.org/10.2165/00002512-199405040-00004
Krusell LR, Jespersen LT, Christensen CK, Thomsen K, Pedersen OL.. Acute natriuresis induced by inhibition of proximal tubular reabsorption of sodium and water in hypertensives following acute calcium entry blockade with nifedipine. J Cardiovasc Pharmacol 1987; 10: S162-3.
Barrett PQ, Bollag WB, Isales CM, McCarthy RT, Rasmussen H. Role of calcium in angiotensin II-mediated aldosterone secretion. Endocr Rev 1989; 10: 496-518. http://dx.doi.org/10.1210/edrv-10-4-496
Nielsen B. Calcium channel blockers the effect on renal changes in clinical and experimental diabetes: an overview. Nephrol Dial Transplant 2000; 15: 581-5. http://dx.doi.org/10.1093/ndt/15.5.581
Sepehr-Ara L, Sepehr-Ara, M, MahmoudianM. Effect of the two new calcium channel blockers mebudipine and dibudipine in comparison to amlodipine on vascular flow of isolated kidney of diabetic rat. Acta Physiol Hung 2010; 97: 281-9
Fortes Meyer KD, Starkey BJ. Simpler flame photometric determination of erythrocyte sodium and potassium : the reference range for apparently healthy adults. Clin Chem 1977; 23: 275-8.
Tabassum M, Mumtaz M, Haleem MA. Electrolyte content of serum, erythrocyte, kidney and heart tissue in salt induced hypertensive rats. Life Sci 1996; 59: 731-7. http://dx.doi.org/10.1016/0024-3205(96)00359-1
Raccah D, Cloudie A, Azulay JP. Erythrocyte Na-K-ATPase activity, metabolic control and neuropathy in IDDM patients. Diabetes Care 1996; 19: 564-8. http://dx.doi.org/10.2337/diacare.19.6.564
Dryer RL, Tammes AR. The determination of phosphorus and phosphatase with n-phenyl-p-phenylenediamine. J Biol Chem 1957; 225: 177-84.
Kang HK, Harvey PW, Valentine JL, Swendseid ME. Zinc, iron, copper, and magnesium concentrations in tissues of rats fed various amounts of zinc. Clin Chem 1977; 23: 4- 1837.
Leblondel G, Allain P. Altered element concentration in tissues of spontaneously hypertensive rats. Biomed Pharmacother 1988; 42: 121-9.
Hallry H, Skypeck HH. Method for determination of serum magnesium. Clin Chem 1964; 10: 391-4.
Chrysant SG. The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension :focus on recent studies. Am J Cardiovasc Drugs 2010; 10: 315-20. http://dx.doi.org/10.2165/11538850-000000000-00000
Fiad TM, Cunningham SK, Hayes FJ, McKenna TJ. Effects of nifedipine treatment on the renin-angiotensin aldosterone axis 1. J Clin Endocrinol Metab 1997; 82: 457-60. http://dx.doi.org/10.1210/jc.82.2.457
Radke KJ, Clendenin RE, Taylor RE Jr. Schneider EG. Calcium dependence of osmolality, potassium, and angiotensin II induced aldosterone secretion. Am J Physiol 1989; 256: E760-4.
Swarts HGP, Bonting SL, De Pont JJHHM, Schuurmans Stek-hoven FMAH, Thien TA, van’t Laar A. Cation fluxes and Na+ -K+ activated ATPase activity in erythrocytes of patients with essential hypertension. Hypertension 1981; 3: 641-9.
Knorr A, De Mendonca M, Garthoff B, Morich F, Kazda S. Chronic treatment with nifedipine prevents development of hypertension and abnormal red cell sodium transport in DahlS-Rats. Arch Int Pharmacodyn Ther 1985; 275: 248-58.
Flaim SF, Irwin JM, Ratz PH, Swigart SC. Differential effects of calcium channel blocking agents on oxygen consumption rate in vascular smooth muscle. Am J Cardiol 1982; 49: 511- 7. http://dx.doi.org/10.1016/S0002-9149(82)80004-0
Pan M, Janis RA. Nimodipine, a new cerebral vasodilator, stimulates Na, K-activated ATPase of smooth muscle microsomes. Fed. Proc., 1982; 41: 1483 (Abstract).
Brock TA, Lewis LJ, Smith JB. Angiotensin increases Na+ entry and Na+ /K+ pump activity in cultures of smooth muscle from rat aorta. Proc Natl Acad Sci USA 1982; 79: 1438-42. http://dx.doi.org/10.1073/pnas.79.5.1438
Zwadlo C, Borlak J. Nifedipine represses ion channels, transporters and Ca2+-binding proteins in hearts of spontaneously hypertensive rats. Toxicol Appl Pharmacol 2006; 213: 224-34. http://dx.doi.org/10.1016/j.taap.2005.10.012
Ebino T, Kimura K, Umemura S.
[Calcium antagonists : current and future applications based on new evidence . Calcium channel blockers and JSH2009]. Clin Calcium 2010; 20: 16-22.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.